Obesity Drug Market Update

Stifel

Tim Opler

Research

253 Pages

Tim Opler gives an overview of the global obesity epidemic and the GLP-1 market.

Key Takeaways

Oral GLP-1 Progress: Several oral GLP-1 candidates are emerging, including one study showing 6.8% weight loss at 26 weeks and another AI-designed oral GLP-1 delivering 8.2–10.3% weight loss in 24 weeks, suggesting pills could become viable alternatives to injections.
Pipeline Intensifying: Dozens of new obesity drugs are being tested across mechanisms (GLP-1, multi-agonists, and combination therapies) as companies try to exceed the ~15–20% weight loss already achieved by current leaders like semaglutide and tirzepatide.
Massive Untreated Market: Despite rapid adoption, over 80% of overweight or obese adults still receive no pharmacologic treatment, leaving a huge addressable market as GLP-1 prescriptions and demand continue rising.
VIEW FULL REPORT

Join our newsletter to have all of this content + Exclusive Newsletter Bonus Content delivered to your inbox every week

Related Content

Market Outlooks
Global Market Perspectives: Hope for the best, ready for the worst
Apr 2026
Markets
Global Market Intelligence: April Update
Apr 2026
China
A Tale of Two Countries: The Real Estate Crises in 1990s Japan and Contemporary China
Apr 2026

The information contained in this communication is of a general nature for informational purposes only, and does not constitute financial, investment, tax or legal advice. The information contained within this communication reflects the opinions of those referenced herein, and do not reflect the opinions of The Idea Farm, L.P. and its affiliates. Such opinions expressed herein are as of the date of production and are subject to change at any time without notice due to various factors, including changing market conditions or tax laws. Where data or information prepared by third parties is presented, no representation, warranty, or undertaking, expressed or implied, is given to the accuracy or completeness of such information by The Idea Farm, L.P. or any other person. While such sources are believed to be reliable, The Idea Farm, L.P. does not assume any responsibility for the accuracy or completeness of such information and does not undertake any obligation to update the information contained herein as of any future date. Any links to third party websites are offered only for use at your own discretion. The Idea Farm L.P., and its affiliates, are separate and unaffiliated from any third parties listed herein and are not responsible for their products, services, policies or the content of their website. All investments are subject to varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy or product referenced directly or indirectly in this communication will be profitable, perform equally to any corresponding indicated historical performance level(s), or be suitable for your portfolio. Past performance is not an indicator of future results.

Scroll to Top